154.F INMODE LTD IS -01
- Market cap
- EUR 683M
- P/E
- 11.4x
- P/B
- 1.22x
- ROE
- 9.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 154.F undervalued?
Graham number154.F trades 21.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
INMODE LTD IS -01 fundamental analysis
No fundamental analysis for INMODE LTD IS -01 yet.
INMODE LTD IS -01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About INMODE LTD IS -01
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatment…
Full company profileINMODE LTD IS -01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
INMODE LTD IS -01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 454M | 492M | 395M | 370M | 355M |
| Gross Profit | 381M | 411M | 317M | 291M | 266M |
| Operating Income | 198M | 196M | 113M | 85.4M | 44.6M |
| EBITDA | 199M | 196M | 113M | 86.1M | 45.3M |
| Net Income | 162M | 198M | 181M | 93.8M | 57.3M |
| EPS | 1.96 | 2.36 | 2.61 | 1.48 | 0.99 |
| Balance Sheet | |||||
| Total Assets | 644M | 863M | 786M | 766M | 720M |
| Total Liabilities | 89.8M | 75.9M | 81.9M | 83.2M | 91.2M |
| Shareholders' Equity | 555M | 787M | 704M | 683M | 629M |
| Cash & Short-term Investments | 97.5M | 144M | 155M | 303M | 396M |
| Cash Flow | |||||
| Operating Cash Flow | 182M | 177M | 133M | 85.3M | 72.9M |
| Capital Expenditure | 1.58M | 705K | 669K | 972K | 766K |
| Free Cash Flow | 180M | 176M | 132M | 84.3M | 72.1M |
| Ratios | |||||
| ROE | 29.1% | 25.1% | 25.8% | 13.7% | 9.1% |
| ROA | 25.1% | 22.9% | 23.1% | 12.2% | 7.9% |
| Net Profit Margin | 35.6% | 40.2% | 45.9% | 25.3% | 16.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
INMODE LTD IS -01 dividends
INMODE LTD IS -01 has not paid dividends in the last 4 fiscal years.
Last stock split: 2:1 on Oct 1, 2021.
Who owns INMODE LTD IS -01
- Insiders 13.16%
- Institutions 55.89%
- Public & others 30.95%
- Shares outstanding 57.5M
- Free float 49.1M
INMODE LTD IS -01 company profile
- Company name
- INMODE LTD IS -01
- Ticker
- 154.F
- ISIN
- IL0011595993
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 660
- Fiscal year end
- December
- Address
- Tavor Building, Yokne'am, Israel, 2069206
- Phone
- 972 4 909 6313
- Website
- inmodemd.com
About INMODE LTD IS -01
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. The company also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions. In addition, it offers hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company sells and markets its products in the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxemburg, Italy, Germany, Austria, Japan, Australia, and India through distributors. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. The company was incorporated in 2008 and is headquartered in Yokne'am, Israel.
INMODE LTD IS -01 management
8- Dr. Michael Kreindel Ph.D.Co-Founder, CTO & Director · born 1968
- Mr. Alon YaariChief Operations Officer
- Ms. Nava Tal-LaunerChief Information Officer
- Mr. Yair MalcaConsultant · born 1978
- Mr. Michael DennisonPresident of North America · born 1981
- Mr. Moshe MizrahyCo-Founder, CEO & Director · born 1953
- Mr. Moshe ItzkovichChief Financial Officer
- Dr. Eran KriegerChief Medical Officer